Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

DRD1 rs4532 polymorphism: A potential pharmacogenomic marker for treatment response to antipsychotic drugs

Full text
Show less -
Ota, Vanessa Kiyomi [1, 2] ; Spindola, Leticia Nery [1] ; Gadelha, Ary [2] ; dos Santos Filho, Airton Ferreira [2] ; Santoro, Marcos Leite [1, 2] ; Christofolini, Denise Maria [3] ; Bellucco, Fernanda Teixeira [1] ; Ribeiro-dos-Santos, Andrea Kely [4] ; Santos, Sidney [4] ; Mari, Jair de Jesus [2] ; Melaragno, Maria Isabel [1] ; Bressan, Rodrigo Affonseca [2] ; Cardoso Smith, Marilia de Arruda [1] ; Belangero, Sintia Iole [1, 2]
Total Authors: 14
[1] Univ Fed Sao Paulo UNIFESP, Disciplina Genet, Dept Morfol & Genet, Sao Paulo - Brazil
[2] Univ Fed Sao Paulo UNIFESP, LiNC Lab Interdisciplinar Neurociencias Clin, Sao Paulo - Brazil
[3] Fac Med ABC FMABC, Dept Ginecol & Obstet, Disciplina Genet & Reprod Humana, Santo Andre - Brazil
[4] Univ Fed Para UFPA, Lab Genet Humana & Med, Belem, Para - Brazil
Total Affiliations: 4
Document type: Journal article
Source: SCHIZOPHRENIA RESEARCH; v. 142, n. 1-3, p. 206-208, DEC 2012.
Web of Science Citations: 20

We investigated the association of dopamine receptor D1 gene (DRD1) rs4532 polymorphism with antipsychotic treatment response in schizophrenia. We have analyzed 124 patients with schizophrenia, consisting of 59 treatment resistant (TR) and 65 non-TR. We found an association between G-allele and TR schizophrenia (p=0.001; adjusted OR=2.71). Setting the common AA-genotype as reference, the GG-homozygous presented a five-fold risk compared to AA-homozygous (p=0.010; OR=5.56) with an intermediate result for AG-genotype (p=0.030; adjusted OR=2.64). The DRD1 rs4532 polymorphism showed a dose-response gradient with increased risk for treatment resistance and may be a potential pharmacogenetic marker for antipsychotic drug treatment response. (C) 2012 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 11/00030-1 - Association study of endocannabinoid system and schizophrenia
Grantee:Síntia Iole Nogueira Belangero
Support type: Regular Research Grants